Buy Reta 30mg at Loti Labs

Molecular structure of Reta

Chemical Name: LY3437943, Synthetic peptide triple hormone receptor agonist

Molecular Formula: C233H364N56O77

Molecular Weight: 5312.8 g/mol

CAS Number: 2381089-83-2

Classification: Triple receptor agonist targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors

Reta is a synthetic peptide engineered as a novel triple glucagon hormone receptor agonist retatrutide. The molecular architecture consists of a single peptide chain conjugated to a fatty diacid moiety through acylation, which extends the half-life to approximately 6 days enabling convenient once-weekly administration for laboratory research purposes. This structural modification significantly improves pharmacokinetic properties and bioavailability compared to shorter-acting compounds.

Mechanism of action

Reta functions as a triple hormone receptor agonist with distinct potency profiles across three critical metabolic pathways. The compound demonstrates approximately 8.9 times greater potency than endogenous GIP at the human gip receptor, 0.4 times the potency of endogenous GLP-1 at GLP-1 receptors, and 0.3 times the potency of glucagon at glucagon receptors.

This engineered receptor agonist reta activates G-protein coupled receptors, initiating adenylate cyclase activation and increasing cyclic adenosine monophosphate (cAMP) levels. The resulting signaling cascades enhance insulin sensitivity, improve glycemic control, reduce food intake through appetite regulation, and increase energy expenditure through glucagon receptor agonism. The synergistic effects of multi-receptor targeting promote weight loss through both reduced caloric intake and enhanced fat burning mechanisms.

The glucagon receptor activation specifically distinguishes Reta from existing weight loss drugs by increasing metabolic rate and promoting substantial reductions in liver fat while maintaining glucose homeostasis through balanced GLP-1 and GIP effects.

Research Studies

Early clinical trials have shown great results for Reta in obesity and metabolic health. In phase 2 placebo controlled trials, Reta achieved mean weight loss of up to 24.2% at 48 weeks in overweight and obese adults, better than current obesity drugs.

The compound has dose dependent efficacy, lower starting dose protocols minimizes gastrointestinal adverse events while maintaining therapeutic benefit. Clinical proof of concept studies show Reta targets multiple pathways simultaneously, better than single receptor weight loss drugs.

Storage and Safety

Reta should be stored between 2°C to 8°C (36°F to 46°F) for laboratory research purposes. Store in original packaging protected from light and contamination. Do not freeze and do not expose to temperatures above 25°C as thermal degradation can affect research outcomes.

Safety profiles from early clinical trials show generally manageable tolerability. Common adverse events are gastrointestinal symptoms like nausea, vomiting and diarrhea which occur at treatment initiation and decrease over time. No serious hypoglycemia related risks have been reported in clinical studies, different from some metabolic treatments.

Proper reconstitution protocols and handling procedures are crucial for compound stability. Research applications should follow established guidelines for peptide handling and storage to ensure consistent results.

Why buy from Loti Labs

Loti Labs offers research grade Reta with high purity standards for obesity management research and metabolic studies. Our triple receptor agonist compounds undergo strict quality control to ensure consistent potency for weight loss mechanisms and energy expenditure pathways.

Key benefits:

• High purity Reta for novel triple glucagon mechanisms
• Batch to batch consistency for reproducible research outcomes
• Competitive pricing for bulk research orders for obesity treatment
• Technical support for research protocols for weight management studies
• Temperature controlled shipping to maintain cold chain integrity
• Documentation to support research compliance and further investigation

Products from Loti Labs are for Research Use Only

Reta from Loti Labs is for research use only. This investigational compound is for in-vitro testing and experimental use only. Human use is strictly prohibited and not FDA approved for human or veterinary use.

This product is not a drug, food or cosmetic under the federal food, compound and cosmetic act and may not be misbranded, mislabeled or misused for human consumption. Reta requires medical supervision in clinical settings and should not be used outside approved clinical trials without proper healthcare provider oversight. Any use beyond research purposes violates intended use and may be dangerous.

Loti Labs Shipping Policy

Loti Labs ships same day for orders placed before 1pm EST Monday through Friday. Orders placed after 1pm EST or weekends ship next business day. Temperature sensitive compounds like Reta receive special cold-chain packaging to maintain product integrity during transit.

We offer special shipping options for compounds that require refrigeration to ensure research materials arrive in optimal condition for immediate use in the lab.

30 Day Money Back Guarantee

Loti Labs offers 30 day money back guarantee on all Reta purchases. Return any unopened products for full refund of purchase price. Our customer service team will assist with any order issues and provide guidance on storage and handling for lab use.

Third Party Testing of Every Batch

Every Reta batch is third party HPLC tested to verify purity and compound identity. Certificate of analysis is included with every shipment to confirm quality control standards exceed industry requirements for research grade peptides.

Our testing protocols ensure consistency for researchers studying Reta in obesity treatment, metabolic diseases and related therapeutic applications.

References

1. Jastreboff AM, et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526.
2. Rosenstock J, et al. Reta, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544.3. Coskun T, et al. LY3298176, a dual GIP and GLP-1 receptor agonist for type 2 diabetes: From discovery to proof of concept. Mol Metab. 2018;18:3-14.
3. Samms RJ, et al. GIPR agonism is weight-independent and insulin sensitizing in obese mice with tirz. J Clin Invest. 2021;131(12):e146353.